Company Filing History:
Years Active: 2023
Title: Innovations in Cancer Immunotherapy by Chen-Hsin Liang
Introduction
Chen-Hsin Liang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer immunotherapy, particularly through his innovative approaches to immune activation and modulation.
Latest Patents
One of his notable patents is titled "Cancer immunotherapy by immune activation or immune modulation via Globo series antigens." This patent outlines a method of immunotherapy for cancer patients, which involves administering vaccines against Globo series antigens, including Globo H, Stage-specific embryonic antigen 3 (SSEA3), and Stage-specific embryonic antigen 4 (SSEA4). Specifically, the method includes administering Globo H-KLH (OBI-822) to patients with metastatic breast cancer. The patent also details a process for selecting suitable cancer patients for immunotherapy and provides therapeutic agents, such as monoclonal antibodies (mAbs) that specifically bind to Globo series antigens and related biomarkers.
Career Highlights
Chen-Hsin Liang is associated with Obi Pharma Inc., where he continues to advance research in cancer treatment. His work has garnered attention for its potential to improve patient outcomes through innovative immunotherapeutic strategies.
Collaborations
He collaborates with esteemed colleagues, including Cheng-Der Tony Yu and Youe-Kong Shue, to further enhance the development of effective cancer therapies.
Conclusion
Chen-Hsin Liang's contributions to cancer immunotherapy exemplify the impact of innovative research in medicine. His work not only addresses critical challenges in cancer treatment but also paves the way for future advancements in immunotherapy.